Mature T-cell leukemias and lymphomas (MaTCL) are rare cancers with limited treatment options, resulting in poor patient outcomes. Current treatments focusing on destroying tumor cells alone have failed to improve survival rates. Recent findings suggest that the immune environment around MaTCL cells may play a key role in disease progression. Our project, ImmuneT-ME, brings together experts in cancer biology, clinical research, data science, and patient advocacy to investigate how the immune environment affects these cancers. Using patient samples, machine learning, and advanced models, we aim to map this immune environment (Objective 1), identify and test potential immune targets for personalized treatment (Objective 2), and ensure our findings are shared with patients and healthcare providers, including creating a European MaTCL patient group (Objective 3). We hope our work will lead to new diagnostic tools and personalized therapies, improving MaTCL care and future clinical trials.

2025

2028